Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Breztri Aerosphere budesonide/ glycopyrronium /formoterol fumarate chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Perseris risperidone Schizophrenia, adults Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Classical Hodgkin lymphoma Reimburse with clinical criteria and/or conditions Complete
Evenity romosozumab Osteoporosis, postmenopausal women Reimburse with clinical criteria and/or conditions Complete
Givlaari givosiran Acute hepatic porphyria (AHP) in adults Reimburse with clinical criteria and/or conditions Complete
Xeomin incobotulinumtoxinA Chronic sialorrhea associated with neurological disorders Reimburse with clinical criteria and/or conditions Complete
Onureg azacitidine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Leqvio inclisiran Primary hypercholesterolemia Do not reimburse Complete
Tagrisso osimertinib Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Tukysa tucatinib Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete